Bio

Annovis Bio Receives Positive Recommendation to Continue Phase 2/3 Trial of Buntanetap for Alzheimer’s Disease Patients From the Independent Data and Safety Monitoring Board (DSMB)

Retrieved on: 
Monday, October 30, 2023

Annovis Bio, Inc. (NYSE: ANVS), announces the positive safety review by the Data and Safety Monitoring Board (DSMB) for its phase 2/3 trial of buntanetap, a drug candidate for moderate to mild Alzheimer’s Disease (AD) patients.

Key Points: 
  • Annovis Bio, Inc. (NYSE: ANVS), announces the positive safety review by the Data and Safety Monitoring Board (DSMB) for its phase 2/3 trial of buntanetap, a drug candidate for moderate to mild Alzheimer’s Disease (AD) patients.
  • The DSMB recommended that Annovis Bio continue the trial as originally designed.
  • To date we have recruited a total of 281 patients out of the planned 320 patients; 76 patients have finished the study.
  • In our Alzheimer’s Disease phase 2 trials, buntanetap was observed to improve cognition and speed of thinking.

Annovis Bio Announces Launch of Proposed Public Offering

Retrieved on: 
Monday, October 30, 2023

The shares of common stock and the accompanying warrant will be issued separately but can only be purchased together in the offering.

Key Points: 
  • The shares of common stock and the accompanying warrant will be issued separately but can only be purchased together in the offering.
  • All of the shares of common stock and the accompanying warrant are being offered by Annovis.
  • The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • A preliminary prospectus supplement and accompanying prospectus describing the terms of the proposed offering will be filed with the SEC.

Dren Bio Strengthens Leadership Team with Appointment of Amit Mehta, Ph.D., as Chief Operating Officer and Chief Business Officer

Retrieved on: 
Monday, October 30, 2023

Dren Bio, Inc. (“Dren Bio” or the “Company”) a clinical-stage biopharmaceutical company developing antibody therapeutics for cancer, autoimmune and other serious diseases, today announced the expansion of its leadership team with the appointment of Amit Mehta, Ph.D., as the Company’s Chief Operating Officer and Chief Business Officer.

Key Points: 
  • Dren Bio, Inc. (“Dren Bio” or the “Company”) a clinical-stage biopharmaceutical company developing antibody therapeutics for cancer, autoimmune and other serious diseases, today announced the expansion of its leadership team with the appointment of Amit Mehta, Ph.D., as the Company’s Chief Operating Officer and Chief Business Officer.
  • Dr. Mehta will be responsible for business development efforts, corporate strategy and leading the operational advancement and expansion of Dren Bio’s pipeline.
  • During his 18-year tenure at Genentech, Dr. Mehta held roles of increasing responsibility that spanned process development, manufacturing, strategy and business development.
  • “We are thrilled to welcome Amit as the newest member of Dren Bio’s leadership team,” said Nenad Tomasevic, Ph.D., Chief Executive Officer of Dren Bio.

Upstream Bio Announces Positive Phase 1b Interim Data in Asthma and Company Progress Toward Phase 2

Retrieved on: 
Tuesday, October 24, 2023

Upstream Bio , a clinical-stage biotech company advancing new therapies to treat inflammation, today announced positive interim results in its Phase 1b clinical study of UPB-101, a thymic stromal lymphopoietin receptor (TSLPR) inhibitor.

Key Points: 
  • Upstream Bio , a clinical-stage biotech company advancing new therapies to treat inflammation, today announced positive interim results in its Phase 1b clinical study of UPB-101, a thymic stromal lymphopoietin receptor (TSLPR) inhibitor.
  • The Phase 1b study is a randomized, double-blinded, placebo-controlled multiple ascending dose (MAD) study with subcutaneous (SC) administration​ conducted in asthma patients.
  • The interim data results demonstrated favorable safety, tolerability, immunogenicity, pharmacokinetic (PK) and pharmacodynamic (PD) markers that strongly support moving to Phase 2.
  • “The Upstream team is taking swift steps to move into our global Phase 2 studies in severe asthma and CRSwNP by Q1 2024.

Aiolos Bio Launches with $245 Million Series A Investment to Advance Development of Novel, Phase 2-Ready TSLP Antibody

Retrieved on: 
Tuesday, October 24, 2023

Aiolos launches with an oversubscribed $245 million Series A investment co-led by Atlas Venture, Bain Capital Life Sciences, Forbion, and Sofinnova Investments with additional investment from RA Capital Management (collectively the “Investor Group”).

Key Points: 
  • Aiolos launches with an oversubscribed $245 million Series A investment co-led by Atlas Venture, Bain Capital Life Sciences, Forbion, and Sofinnova Investments with additional investment from RA Capital Management (collectively the “Investor Group”).
  • The Company will advance its lead drug candidate, AIO-001, into a Phase 2 clinical trial in moderate-to-severe asthma patients and is actively evaluating additional development opportunities.
  • AIO-001 is an anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody that has the potential to be administered only twice per year due to its differentiated potency and long half-life.
  • Aiolos Bio acquired exclusive rights for global development and commercialization of the drug outside of greater China from Jiangsu Hengrui Pharmaceuticals Co., Ltd (“Hengrui”) in August 2023.

Pivot Bio Named to TIME’s List of the Best Inventions of 2023

Retrieved on: 
Tuesday, October 24, 2023

Pivot Bio, Inc ., a sustainable agriculture company, is named to TIME’s annual list of the Best Inventions, which features 200 extraordinary innovations changing our lives, for the second time.

Key Points: 
  • Pivot Bio, Inc ., a sustainable agriculture company, is named to TIME’s annual list of the Best Inventions, which features 200 extraordinary innovations changing our lives, for the second time.
  • Pivot Bio is recognized for the company’s introduction of PROVEN® 40 OS, which enables corn farmers to seamlessly plant their seeds with up to 25% of the crop’s nitrogen needs already in place.
  • By introducing its products as a seed coating, Pivot Bio is making microbial nitrogen broadly accessible and has unlocked new markets all around the world.
  • “Pivot Bio’s on-seed technology is helping to change something that has been done the same way for over 100 years, upending a $190B industry,” said Chris Abbott, CEO.

Annovis Bio Showcases Promising Progress in Novel Drug Development at the 2023 Clinical Trials on Alzheimer's Disease Conference

Retrieved on: 
Tuesday, October 24, 2023

Annovis Bio, Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), is presenting two posters at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 annual conference held in Boston, Massachusetts, from October 24-27.

Key Points: 
  • Annovis Bio, Inc. (NYSE: ANVS), a late-stage clinical drug platform company developing transformative therapies to treat neurodegenerative diseases, including Alzheimer’s Disease (AD) and Parkinson’s Disease (PD), is presenting two posters at the Clinical Trials on Alzheimer's Disease (CTAD) 2023 annual conference held in Boston, Massachusetts, from October 24-27.
  • This novel mechanism of action makes Annovis' drug a potentially effective treatment option for AD and also for PD.
  • The posters' collective findings highlight a highly promising treatment for neurodegenerative conditions like Alzheimer's disease and Parkinson's disease.
  • Cheng Fang , Ph.D., senior vice president of research and development at Annovis Bio, is presenting two posters at CTAD.

Mission Bio Announces High Precision Detection of Variants For Tapestri® Platform in NIST Genome Editing Consortium Initial Study

Retrieved on: 
Monday, October 23, 2023

Mission Bio , a leader in single-cell multi-omic solutions for precision medicine, announced today initial results from the National Institute of Standards and Technology (NIST) Genome Editing Consortium's inaugural Interlab Study.

Key Points: 
  • Mission Bio , a leader in single-cell multi-omic solutions for precision medicine, announced today initial results from the National Institute of Standards and Technology (NIST) Genome Editing Consortium's inaugural Interlab Study.
  • The NIST Genome Editing Consortium (GEC) was created to meet the growing demand for enhancing the confidence in genome editing technologies by supporting quality and standardization in analysis.
  • In 2018, Mission Bio joined the consortium to provide single-cell resolution of genome editing outcomes.
  • The one-day public workshop hosted by NIST will discuss current and future efforts of the NIST Genome Editing Consortium.

Ayana Bio Launches Plant Cell Advantage™ Portfolio with Three New Health and Wellness Ingredients

Retrieved on: 
Monday, October 23, 2023

BOSTON, Oct. 23, 2023 /PRNewswire/ -- Ayana Bio, the plant cell technology company making sustainable bioactives for consumer products, today announced the launch of its Plant Cell Advantage™ (PCA™) ingredient portfolio, including Dog Rose PCA™, Hedge Nettle PCA™, and Sage PCA™ as the latest additions in its offering of plant cell-cultivated health and wellness ingredients.

Key Points: 
  • Ayana Bio will debut Plant Cell Advantage™ Dog Rose, Hedge Nettle, and Sage ingredients to deliver the health benefits of high-quality plant bioactives
    BOSTON, Oct. 23, 2023 /PRNewswire/ -- Ayana Bio , the plant cell technology company making sustainable bioactives for consumer products, today announced the launch of its Plant Cell Advantage™ (PCA™) ingredient portfolio, including Dog Rose PCA™, Hedge Nettle PCA™, and Sage PCA™ as the latest additions in its offering of plant cell-cultivated health and wellness ingredients.
  • The new Plant Cell Advantage™ ingredients are non-GMO plant powders with standardized hallmark bioactive compositions and can directly replace dog rose, hedge nettle and sage in dietary supplements and food products.
  • Ayana Bio's Plant Cell Advantage™ ingredients are developed using plant cell cultivation – a means to create plant materials without growing plants in the ground.
  • If you are interested in being one of the first companies to formulate your products with Plant Cell Advantage™ ingredients, contact Ayana Bio at www.ayanabio.com/contact .

Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases

Retrieved on: 
Tuesday, October 17, 2023

Gilead’s initial equity investment at a premium represents 19.9 percent of the outstanding voting stock of Assembly Bio as of the date of closing.

Key Points: 
  • Gilead’s initial equity investment at a premium represents 19.9 percent of the outstanding voting stock of Assembly Bio as of the date of closing.
  • In addition, subject to certain conditions, Gilead has agreed to purchase up to 29.9 percent of Assembly Bio’s outstanding voting stock at a premium.
  • For future new programs, Assembly Bio will also have an option to co-promote those products in the United States.
  • Management from Assembly Bio will be hosting an investor webcast today at 8:30 a.m. ET/5:30 a.m. PT to discuss the Gilead partnership.